Please wait while the transcript is being prepared...
0:00
Hi, my name is Derek O'Hagan.
I'm a senior advisor and
senior fellow in GSK.
I'm going to talk about
vaccine adjuvants.
I'm really going to
dive into the science
behind vaccine adjuvants,
tell you about the approaches
we have that are established,
and also highlight some
of the new approaches that will
be emerging in the near future.
0:24
It's probably important
to start off with a basic
understanding of what
a vaccine adjuvant is.
This slide tries to
illustrate that.
Essentially, it's got
a theoretical vaccine
in blue with no
vaccine adjuvant,
and then the vaccine
adjuvant added in orange.
In essence, the
adjuvant is there
to enhance immune responses
to co-administer antigens
which are typically
recombinant or sub
unit approaches,
or that could be whole
viruses, kill viruses.
It can manifest with a
more rapid response,
a stronger, broader response,
or an extended
duration of response,
or more of those in combination.
In essence, the vaccine
adjuvant is there to enhance
the immune response to
the vaccine antigen.
1:09
Vaccine adjuvants are
not a new concept.
Essentially, they've been
around for almost 100 years.
If you look at the
bottom of this slide,
you see the established
insoluble aluminium salts
have been utilized in
combination vaccines,
which are still utilized
in the routine
children vaccines,
DT, TT, pertussis etc.
They've been around
for a long time,
shown to be safe and effective,
but new approaches
have only emerged
relatively recently
on the time line.
It was really MF59 which is
an oil and water emulsion
which changed things at the
end of the 20th century.
Then you see in orange
the adjuvant system
approach of GSK,
AS03, AS04, etc,
which have also emerged now.
I'll talk a little
bit more about them.
